- Breaking News Three hurt in Rodeo gas explosion
- Breaking News Anne Marie Fuller:
- Breaking News Salwan: Swine flu: The saga continues
- Breaking News Food and wine events
Controversy spikes over anti-diabetes drug Avandia
0 Comments | AFP, June, 2007
WASHINGTON (AFP) — Controversy over diabetes drug Avandia heated up Wednesday as experts pointed to studies linking it to greater heart attack risk, while a GSK study claimed rosiglitazone is safe.
The GlaxoSmithKline study published online Tuesday by the New England Journal of Medicine (NEJM) gave preliminary results of a four-year clinical study of 4,446 patients showing Avandia did not increase the rate of heart attacks or death.
Among the sub-group of patients who took Avandia, 29 died from heart attacks, against 35 who died from a control group taking two other drugs for adult-onset, type 2 diabetes, GSK said in the study.
In a study that analyzed 42 clinical trials published May 21 by NJEM, eminent cardiologist Steven Nissen of the Cleveland Clinic, in...
- Made from scratch: When Honda built a plant in Alabama it also built a workforce-using local workers who had no experience in making cars - Recruitment & Hiring
- Portfolio forecasting tools: what you need to know
- Kemarie McMinn Named Executive Vice President of Halo Debt Solutions, Inc.
- Halo Debt Solutions, Inc. Supports Push Toward Industry Regulation
- Traction Named #1 Interactive Agency for 2009 by BtoB Magazine
- Halo Debt Solutions, Inc. Gives Debt Settlement a Face-Lift
- Banking technology, technological learning and competition: comparative case studies in Thai banking
- Empirically assessing the impact of BPR on banking firms